Aficamten vs Placebo in Symptomatic Non-Obstructive HCM

Market
100%75%50%25%0%Apr 26 • YES 58.0%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
6/1/26
Study Completion
9/1/26
Sponsor
Cytokinetics
Ticker
$CYTK
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
500
NCT
NCT06081894
Trial Description
Phase 3 ACACIA-HCM is a randomized, double-blind, placebo-controlled trial of oral aficamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy. The study is evaluating effects on health status and exercise capacity, with co-primary endpoints of change in KCCQ-CSS and pVO2 at Week 36.